Polyphenols: Potential anti‐inflammatory agents for treatment of metabolic disorders

Abstract Ample evidence highlights the potential benefits of polyphenols in health status especially in obesity‐related metabolic disorders such as insulin resistance, type 2 diabetes, and cardiovascular diseases. Mechanistically, due to the key role of “Metainflammation” in the pathomechanism of metabolic disorders, recently much focus has been placed on the properties of polyphenols in obesity‐related morbidities. This narrative review summarizes the current knowledge on the role of polyphenols, including genistein, chlorogenic acid, ellagic acid, caffeic acid, and silymarin in inflammatory responses pertinent to metabolic disorders and discusses the implications of this evidence for future directions. This review provides evidence that the aforementioned polyphenols benefit health status in metabolic disorders via direct and indirect regulation of a variety of target proteins involved in inflammatory signaling pathways. However, due to limitations of the in vitro and in vivo studies and also the lack of long‐term human clinical trials studies, further high‐quality investigations are required to firmly establish the clinical efficacy of the polyphenols for the prevention and management of metabolic disorders.